TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04582760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early mobilization
Description: In patients who require mechanical ventilation for acute respiratory failure or sepsis (non-malignant tumor patients), early mobilization will be performed in addition to conventional bedside physical therapy, for 30 mins per session, two sessions per day, 7 days per week until the patients are discharged from the ICU.
Study: NCT00544869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061 （Tolvaptan)
Description: 15-30mg/day,daily for 14days
Study: NCT02077790

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: CASIA Cornea/Anterior Segment OCT SS-1000
Description: The SS-1000 is a three-dimensional, non-contact, non-invasive high resolution optical coherence tomography imaging device based on the principal of Swept Source OCT. The system achieves high resolution imaging of 10 μm (Axial) and 30 μm (Transverse) and high speed scanning of 30,000 A-scans per second.
Study: NCT00771472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Parts I \& II: Vorinostat (400 mg) Oral, daily (QD). Treatment period is 28 days per cycle.
Study: NCT01936220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuity of specialized care
Description: Continuity of care in treatment and professional caregiver was given during 5 year. Treatment targets included relapse prevention through recognition of prodromal symptoms, coping with negative symptoms and stress, increasing medication adherence, decrease of substance use, prevention of drop-out and stimulating and supporting participation in structural activities (work and/or education).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuity of specialized care
Description: Continuity of care in treatment and professional caregiver was given during 5 year. Treatment targets included relapse prevention through recognition of prodromal symptoms, coping with negative symptoms and stress, increasing medication adherence, decrease of substance use, prevention of drop-out and stimulating and supporting participation in structural activities (work and/or education).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent groups combined with Continuity of Specialized care
Description: Approximately fifty parent group therapy sessions will be held in a flexible way over a 60 month period. Each parent group was run by two experienced family therapists.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discontinuity of care, non specialised care
Description: Standard Treatment as usual (TU) was provided during 5 years by local mental health care professionals situated nearby the domicile of patients. TU had comparable treatment targets as ST but was not provided by treatment staff specialized in early intervention in schizophrenia or related disorders. However, TU was (like ST) sustained and dedicated to prevent psychotic relapse and improve social functioning.
Study: NCT00667576

Intervention type: DRUG
Group type: OTHER
Intervention: Maxacalcitol
Description: Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
Study: NCT03048955

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Superion® IDS
Description: Device is a non-fusion, spinal column load-sharing device used to stabilize the spine at the implanted leve

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct decompression Surgery
Description: A surgical procedure - the control
Study: NCT00132041

Intervention type: DEVICE
Group type: OTHER
Intervention: radiofrequency ablation
Study: NCT01483430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginseol Kg1 (low dose)
Description: 1 capsule/day (100mg of Ginseol Kg1), Duration: 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginseol Kg1(high dose)
Description: 1 capsule/day (300mg of Ginseol Kg1), Duration: 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule/day (starch), Duration: 8 weeks
Study: NCT01171820

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS® Liberté™
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE V® EECSS
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
Study: NCT02172157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL i.v.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1744 CL oral
Study: NCT01358032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an in-home cognitive behavioral program
Description: The in-home cognitive behavioral program aims to learn older persons, living in the community, how to deal with concerns about falling and to increase physical, social and functional activity. The principles of cognitive restructuring are used for shifting maladaptive in adaptive attitudes with respect to falling as well as increasing self efficacy beliefs and feelings of control. The following themes are discussed during the program: concerns about falling, thoughts about falling, physical exercise, assert oneself, overcome personal barriers, recognizing fall-ty habits and managing concerns about falling. Duration of the program is 10 weeks with 7 individual sessions (3 home visits (60, 60 and 75 minutes, respectively) \& 4 telephone contacts (35 minutes each). The program is facilitated by trained nurses qualified in the field of geriatrics and working for home care agencies.
Study: NCT00483886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 2 mg o.d.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo o.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 4 mg o.d.
Study: NCT02780076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional training program
Description: Patients treated for hip fracture participate in a functional training program during their short-term stays at nursing homes. The program is initiated by the nurses 4 times a day for 3 weeks as part of the habitual routine.
Study: NCT00956943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicoderm CQ transdermal nicotine
Description: Transdermal nicotine patch (21mg vs. 42mg), 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm CQ transdermal nicotine
Description: Transdermal nicotine patch (21mg vs. 42mg), 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo patch
Study: NCT03706703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: continuous intravenous infusion Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel is 75 mg/m2 intravenously over 1 hour on Day 1 of each 21-day cycle
Study: NCT03706703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin is administered on Day 1 of each 21-day，followed by docetaxol or pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: pemetrexed is 500 mg/m2 intravenously on Days 1 of each 21-day cycle
Study: NCT00809328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: The intravenous formulation 500 mg is administered once daily for 2-5 days; followed by the oral formulation 500 mg will be given once daily to complete a 7 to 10-day course of therapy.
Study: NCT01172756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: 0.5 mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: 1 mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: 2 mg single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose
Study: NCT02020044

Intervention type: OTHER
Group type: OTHER
Intervention: Endothelial Keratoplasty
Study: NCT05055232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621
Description: tablets, dosage ranged from 50 mg to 600 mg, quaque die（QD）with the meal.
Study: NCT03125278

Intervention type: OTHER
Intervention: Medication knowledge
Description: Participants will be asked questions over the phone about their medications

Intervention type: OTHER
Intervention: Medication knowledge
Description: Participants will be asked questions over the phone about their medications
Study: NCT00690651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early mobilization
Description: pt to get out of bed and mobilize with physiotherapist within 24 hours of surgery. they will be allowed toilet privileges and will go home when safe (as per medical staff and allied health)
Study: NCT02140255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Description: Chosen by the site investigator and dosed according to World Health Organization (WHO) or individual country or local standard guidelines.
Study: NCT00690651

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard mobilization
Description: this group will rest in bed with their leg elevated above their heart for 48 hours post surgery to ankle fracture and will then mobilize with physiotherapist with aim to discharge home.
Study: NCT03065660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone, Oral, 200 Mg
Description: The Investigational Medicinal Product (IMP) is a single dose of 200mg mifepristone to be taken orally after confirmation of missed miscarriage by pelvic ultrasound scan.
Study: NCT03648866

Intervention type: OTHER
Intervention: interview
Description: Initial interview and potential follow-up interviews and focus group with Florida Hospital employees.~Interview participants in compassion rounds

Intervention type: OTHER
Intervention: interview
Description: Initial interview and potential follow-up interviews and focus group with Florida Hospital employees.~Interview participants in compassion rounds
Study: NCT03065660

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The placebo will be an oral tablet in the same form as the IMP, and identical in appearance.
Study: NCT03043781

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous epidural infusion
Description: Continuous infusion, 5 ml/h
Study: NCT00985920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues.
Study: NCT03043781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent epidural bolus
Description: Intermittent bolus 5 ml every hour
Study: NCT01952951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine Oxaliplatin
Description: after completion of chemoradiation, two cycles of capecitabine (850mg/m2 twice daily from D1 evening to D15 morning) and oxaliplatin (100mg/m2 on D1) will be administered every 3 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: pelvic radiation capecitabine 5-fluorouracil
Description: 50.4Gy of pelvic radiation with capecitabine or 5-fluorouracil
Study: NCT03962673

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: NB-UVB light exposure
Description: Participants are exposed to three low dose Narrow Band UVB light.
Study: NCT02605395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDIAZOLE 20mg DR tabs
Description: IDIAZOLE 20mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDIAZOLE 20mg DR tabs
Description: IDIAZOLE 20mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARIET 20 mg DR tabs
Description: PARIET 20 mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg rabeprazole sodium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARIET 20 mg DR tabs
Description: PARIET 20 mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg rabeprazole sodium.
Study: NCT00383656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: 75 ng/kg GnRH IV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pump
Description: portable, infusion pump for GnRH
Study: NCT00985920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues.
Study: NCT01772030

Intervention type: OTHER
Group type: OTHER
Intervention: Use of the Achieve catheter followed by ICE-guided mapping catheter
Study: NCT03310697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of blood and urine samples
Description: For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: The other clinical data, any other biological samples or additional examinations are done under the opinion of the clinician or the neuropediatrics.
Study: NCT03447717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiGait
Description: implanted device for peroneal nerve stimulation
Study: NCT00881322

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BC-130 (Gas Defense)
Description: Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Gas Defense Serving Size: 1 tablet Active Ingredients: B. Coagulans, Enzyme Blend (Cellulase - Trichoderma longibrachiatum, Cellulase - Aspergillus niger, Hemicellulase, Alpha Galactosidase, Invertase) Inactive Ingredients: vegetable capsule, Magnesium Stearate, Silicon Dioxide, Maltodextrin Contains: Wheat, Fish.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Placebo - matched in size and color to the active product Inactive Ingredients: microcrystalline cellulose, FD\&C yellow #5 Lake, FD\&C blue #1 Lake, FD\&C red #46 Lake and vegetable capsule
Study: NCT05867095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical navigation
Description: Patients will be operated with assistance of a navigation system

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional
Description: Patients will be operated using the conventional technique
Study: NCT01216566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occiflex Device
Description: This device is a computerized robotic platform that allows continuous mobilization of the cervical spine in a three dimensional space. The patients undergoes biweekly 20 minute therapeutic session for 6 weeks
Study: NCT00086996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Before surgery: 180 mg/m2/day by 24-hour infusion days 8 through 43. After surgery:180 mg/m2/day by 24-hour infusion days 1 through 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Before surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29. After surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: The surgical technique will depend upon the location and extent of tumor and individual surgeon preference.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Starting Day 8, patients will be treated 5 days/week at 180 centigray (cGy)/day times 25 fractions to a total dose of 4,500 cGy.
Study: NCT01798212

Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopic full thickness plication
Study: NCT01814462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6 months CPAP
Study: NCT01952951

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: pelvic radiation capecitabine 5-fluorouracil
Description: 50.4Gy of pelvic radiation with capecitabine or 5-fluorouracil
Study: NCT02251639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POS + PS2 + VELscope
Description: Oral cavity examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device.
Study: NCT02140255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Description: Chosen by the site investigator and dosed according to World Health Organization (WHO) or individual country or local standard guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Description: Chosen by the site investigator and dosed according to World Health Organization (WHO) or individual country or local standard guidelines.
Study: NCT03656783

Intervention type: DRUG
Group type: OTHER
Intervention: Biktarvy
Description: Open-label, multicenter, single-arm study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine/Dolutegravir (ABC/3TC/DTG) to the Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-Infected Adult Subjects
Study: NCT03148886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PA intervention
Description: The program is individualized according to age, fitness level, place of residence, access to adapted specific training group or associations, PA preferences and wishes of each participant. Patients are informed of the recommendations in terms of PA, and the target of 150min per week in order to maintain health benefits. Patients are asked to walk at least 30 minutes per day and increase their activities into daily routine. Several individual strategies are established with the patients to attain their objectives and increase their daily life PA.~Withings® PA trackers have been used to provide an incentive effect to increase PA, to measure the number of steps per day and make people think about their PA. Patients wore a Withings Go® wristband PA tracker throughout the whole study and had in real time a feedback on their number of steps per day.~A 7 mL blood sample is collected at baseline (D1) and at the end of the 6-month study (M6) for the biological study.